Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nicholas S Downing

Showing results (11-20 of 47) with videos related to

Pageof 5
Sort By:
The New England Journal of Medicine|June 29, 2017
Regulatory Review of New Therapeutic AgentsNicholas S Downing, Audrey D Zhang, Joseph S Ross
JAMA|October 5, 2017
Characteristics of Novel Therapeutics and Postmarket Safety Events-ReplyNicholas S Downing, Nilay D Shah, Joseph S Ross
BMJ Open|February 10, 2017
Assessing the potential clinical impact of reciprocal drug approval legislation on access to novel therapeutics in the USA: a cohort studyMatthieu Larochelle, Nicholas S Downing, Joseph S Ross, et al.
Nature Reviews. Drug Discovery|October 6, 2015
Regulatory watch: Characterizing the US FDA's approach to promoting transformative innovationNicholas S Downing, Harlan M Krumholz, Joseph S Ross, et al.
Archives of Internal Medicine|April 12, 2012
Avoidance of generic competition by Abbott Laboratories' fenofibrate franchiseNicholas S Downing, Joseph S Ross, Cynthia A Jackevicius, et al.
JAMA Internal Medicine|May 7, 2014
Descriptions and interpretations of the ACCORD-Lipid trial in the news and biomedical literature: a cross-sectional analysisNicholas S Downing, Theresa Cheng, Harlan M Krumholz, et al.
British Journal of Clinical Pharmacology|March 27, 2015
Regulatory review time and post-market safety events for novel medicines approved by the EMA between 2001 and 2010: a cross-sectional studyJean-David Zeitoun, Jérémie H Lefèvre, Nicholas S Downing, et al.
Pharmacoepidemiology and Drug Safety|November 12, 2015
Regulatory anticipation of postmarket safety problems for novel medicines approved by the EMA between 2001 and 2010: a cross-sectional studyJean-David Zeitoun, Jérémie H Lefèvre, Nicholas S Downing, et al.
The New England Journal of Medicine|November 1, 2018
Complements from the LungNicholas S Downing, Ciaran J McMullan, Helmut G Rennke, et al.
JAMA|January 23, 2014
Clinical trial evidence supporting FDA approval of novel therapeutic agents, 2005-2012Nicholas S Downing, Jenerius A Aminawung, Nilay D Shah, et al.
Pageof 5

Showing results (11-20 of 47) with videos related to

Sort By:
Pageof 5
The New England Journal of Medicine|June 29, 2017
Regulatory Review of New Therapeutic AgentsNicholas S Downing, Audrey D Zhang, Joseph S Ross
JAMA|October 5, 2017
Characteristics of Novel Therapeutics and Postmarket Safety Events-ReplyNicholas S Downing, Nilay D Shah, Joseph S Ross
BMJ Open|February 10, 2017
Assessing the potential clinical impact of reciprocal drug approval legislation on access to novel therapeutics in the USA: a cohort studyMatthieu Larochelle, Nicholas S Downing, Joseph S Ross, et al.
Nature Reviews. Drug Discovery|October 6, 2015
Regulatory watch: Characterizing the US FDA's approach to promoting transformative innovationNicholas S Downing, Harlan M Krumholz, Joseph S Ross, et al.
Archives of Internal Medicine|April 12, 2012
Avoidance of generic competition by Abbott Laboratories' fenofibrate franchiseNicholas S Downing, Joseph S Ross, Cynthia A Jackevicius, et al.
JAMA Internal Medicine|May 7, 2014
Descriptions and interpretations of the ACCORD-Lipid trial in the news and biomedical literature: a cross-sectional analysisNicholas S Downing, Theresa Cheng, Harlan M Krumholz, et al.
British Journal of Clinical Pharmacology|March 27, 2015
Regulatory review time and post-market safety events for novel medicines approved by the EMA between 2001 and 2010: a cross-sectional studyJean-David Zeitoun, Jérémie H Lefèvre, Nicholas S Downing, et al.
Pharmacoepidemiology and Drug Safety|November 12, 2015
Regulatory anticipation of postmarket safety problems for novel medicines approved by the EMA between 2001 and 2010: a cross-sectional studyJean-David Zeitoun, Jérémie H Lefèvre, Nicholas S Downing, et al.
The New England Journal of Medicine|November 1, 2018
Complements from the LungNicholas S Downing, Ciaran J McMullan, Helmut G Rennke, et al.
JAMA|January 23, 2014
Clinical trial evidence supporting FDA approval of novel therapeutic agents, 2005-2012Nicholas S Downing, Jenerius A Aminawung, Nilay D Shah, et al.
Pageof 5